Immunicum receives regenerative medicine advanced therapy designation from FDA for ilixadencel in kidney cancer

6 May 2020 - Immunicum announced today that it has received regenerative medicine advanced therapy designation from the U.S. FDA for ...

Read more →

Antabio receives FDA qualified infectious disease product designation for MEM-ANT3310, a novel broad-spectrum combination therapy targeting WHO’s priority pathogens

6 May 2020 - QIDP is granted to Antabio’s MEM-ANT3310 for major hospital indications including nosocomial pneumonia. ...

Read more →

FDA approves first targeted therapy to treat aggressive form of lung cancer

6 May 2020 - Today, the U.S. FDA approved Tabrecta (capmatinib) for the treatment of adult patients with non-small cell lung ...

Read more →

Bristol Myers Squibb provides update on biologics license application for lisocabtagene maraleucel

6 May 2020 - Bristol Myers Squibb today announced that the U.S. FDA has extended the action date by three ...

Read more →

Chiesi files resubmission to address FDA Bronchitol (mannitol) inhalation powder complete response letter

5 May 2020 - Pharmaxis today announced its US licensee Chiesi has filed a resubmission that addresses the issues raised ...

Read more →

Kala Pharmaceuticals resubmits new drug application for Eysuvis for dry eye disease

4 May 2020 - Kala Pharmaceuticals today announced that it has resubmitted its new drug application to the U.S. FDA for ...

Read more →

FDA approves new treatment for a type of heart failure

5 May 2020 - Today, the U.S. FDA approved Farxiga (dapagliflozin) oral tablets for adults with heart failure with reduced ejection ...

Read more →

Pfizer and Biontech dose first participants in the U.S. as part of global COVID-19 MRNA vaccine development program

5 May 2020 - Pfizer and BioNTech ramping up manufacturing capabilities to further increase production capacity in 2020/2021. ...

Read more →

Overlap weighting: a propensity score method that mimics attributes of a randomised clinical trial

5 May 2020 - Evidence obtained from clinical practice settings that compares alternative treatments is an important source of information about ...

Read more →

GeneTx and Ultragenyx announce GTX-102 granted fast track designation by US FDA for treatment of Angelman syndrome

4 May 2020 - GeneTx Biotherapeutics and Ultragenyx today announced that the U.S. FDA has granted fast track designation to GTX-102 ...

Read more →

Teva and Celltrion Healthcare announce the launch of Truxima (rituximab-abbs) injection for rheumatoid arthritis, the only biosimilar to Rituxan (rituximab) available in the United States for this indication

4 May 2020 - Truxima is also now available for the treatment of granulomatosis with polyangiitis (Wegener’s granulomatosis) and microscopic polyangiitis. ...

Read more →

Gilead's drug pricing in the crosshairs again in wake of OK to use remdesivir against COVID-19

4 May 2020 - Gilead plans to spend $1 billion on its COVID-19 drug remdesivir. Now some members of Congress ...

Read more →

Randomised clinical trials and COVID-19: managing expectations

4 May 2020 - Despite the millions of cases and hundreds of thousands of deaths that have occurred in this devastating ...

Read more →

U.S. law makers question Jaguar Health on price hike of drug that may help treat COVID-19 patients

4 May 2020 - The chair of a House of Representatives committee and a fellow Democratic committee member on Monday ...

Read more →

How remdesivir, new hope for COVID-19 patients, was resurrected

4 May 2020 - The drug failed as a treatment for hepatitis and Ebola. With federal funding, scientists trained it on ...

Read more →